| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$50,235,035 |
|
|
|
Indirect Value
|
$10,282,624 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,517,659 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
S |
$181.01 |
$3,110,114 |
D/D |
(17,182) |
41,939 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-12-14 |
4 |
D |
$179.13 |
$1,502,184 |
D/D |
(8,386) |
43,036 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
D |
$293.68 |
$4,501,821 |
D/D |
(15,329) |
43,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
OE |
$30.63 |
$612,600 |
D/D |
20,000 |
43,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-06 |
4 |
S |
$562.37 |
$11,260,068 |
D/D |
(20,000) |
44,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
OE |
$21.25 |
$431,269 |
D/D |
20,295 |
44,245 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-12 |
4 |
D |
$324.44 |
$10,361,316 |
D/D |
(31,936) |
47,003 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-06 |
4 |
OE |
$21.25 |
$743,750 |
D/D |
35,000 |
48,527 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-12-17 |
4 |
OE |
$16.80 |
$99,994 |
D/D |
5,952 |
48,988 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-13 |
4 |
S |
$276.71 |
$6,378,806 |
D/D |
(23,038) |
48,988 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
OE |
$52.03 |
$7,815,575 |
D/D |
52,500 |
49,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-03-30 |
4 |
AS |
$45.00 |
$346,140 |
D/D |
(7,692) |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-05 |
4 |
AS |
$45.83 |
$1,572,656 |
D/D |
(34,115) |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-07 |
4 |
AS |
$67.47 |
$2,354,375 |
D/D |
(33,760) |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-12 |
4 |
OE |
$16.80 |
$1,094,406 |
D/D |
54,548 |
50,807 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,020 |
50,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
OE |
$20.32 |
$199,994 |
D/D |
9,483 |
51,422 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
D |
$843.79 |
$682,626 |
D/D |
(809) |
51,891 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$351,028 |
D/D |
(466) |
51,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-11 |
4 |
D |
$844.09 |
$611,965 |
D/D |
(725) |
52,019 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-07 |
4 |
S |
$947.34 |
$7,637,954 |
D/D |
(8,037) |
52,019 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
330 |
52,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
52,700 |
0 |
- |
|
140 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
